In the future, randomized and prospective clinical trials are necessary to investigate the efficacy and safety of radiotherapy plus EGFR TKIs and to determine the optimal treatment strategy for NSCLC patients with EGFR mutations and BMs. Here, EGFR is linked to non-small cell lung carcinoma.